ExLibris header image
SFX Logo
Title: A phase 1 dose escalation study of bortezomib combined with rituximab, cyclophosphamide, doxorubicin, modified vincristine, and prednisone for untreated follicular lymphoma and other low-grade B-cell lymphomas
Source:

Cancer [0008-543X] Sinha, Rajni yr:2012


Collapse list of basic services Basic
Full text
Full text available via Wiley Online Library Free Backfiles
GO
Document delivery
Request document via Library/Bibliothek GO
Users interested in this article also expressed an interest in the following:
1. Tilly, H. "Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial." Lancet 377.9759 (2011): 42-51. Link to SFX for this item
2. Sparano, Joseph A. "Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma." Blood 115.15 (2010): 3008-3016. Link to SFX for this item
3. Lowry, L. "Has Single-Agent Rituximab Replaced Watch-and-Wait for a Patient With Asymptomatic Low-Grade Follicular Lymphoma?." The cancer journal 18.5 (2012): 390-395. Link to SFX for this item
4. Tobinai, K. "Randomized phase II study of concurrent and sequential combinations of rituximab plus CHOP (cyclophosphamide, doxorubicin, vincristine and prednisolone) chemotherapy in untreated indolent B-cell non-Hodgkin lymphoma: 7-year follow-up results." Cancer Science 101.12 (2010): 2579-2585. Link to Full Text for this item Link to SFX for this item
5. Gomber, S. "Vincristine induced neurotoxicity in cancer patients." Indian journal of pediatrics 77.1 (2010): 97-100. Link to SFX for this item
6. Ardeshna, Kirit M. "Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial." Lancet oncology 15.4 (2014): 424-435. Link to SFX for this item
7. Baila, C. "Gem-(R)CHOP versus (R)CHOP: a randomized phase II study of gemcitabine combined with (R)CHOP in untreated aggressive non-Hodgkin's lymphoma--EORTC lymphoma group protocol 20021 (EudraCT number 2004-004635-54)." European journal of haematology 86.2 (2011): 111-6. Link to Full Text for this item Link to SFX for this item
8. Friedberg, J. "Rituximab maintenance in follicular lymphoma: PRIMA." Lancet 377.9759 (2011): 4-6. Link to SFX for this item
9. Hochster, H. "Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 Study." Journal of clinical oncology 27.10 (2009): 1607-14. Link to SFX for this item
10. Marcus, Robert, A. "The therapeutic use of rituximab in non-Hodgkin's lymphoma." European journal of haematology 78.67 (2007): 5-14. Link to Full Text for this item Link to SFX for this item
11. Federico, M. "R-CVP versus R-CHOP versus R-FM as first-line therapy for advanced-stage follicular lymphoma: Final results of FOLL05 trial from the Fondazione Italiana Linfomi (FIL)." Journal of clinical oncology 30.15_suppl (2012): 8006-. Link to SFX for this item
12. Fan, W. "G2 checkpoint abrogator abates the antagonistic interaction between antimicrotubule drugs and radiation therapy." Radiotherapy and oncology 104.2 (2012): 243-8. Link to SFX for this item
13. Lukas, P. "Feasibility and toxicity of concomitant radio/immunotherapy with MabThera (Rituximab®) for patients with non-Hodkin's Lymphoma: results of a prospective phase I/II study." Strahlentherapie und Onkologie 187.5 (2011): 300-305. Link to Full Text for this item Link to SFX for this item
14. Haura, Shirish B. "A phase II study of PD-0325901, an oral MEK inhibitor, in previously treated patients with advanced non-small cell lung cancer." Clinical cancer research 16.8 (2010): 2450-2457. Link to SFX for this item
15. Traina, Tiffany A. "Feasibility trial of letrozole in combination with bevacizumab in patients with metastatic breast cancer." Journal of clinical oncology 28.4 (2010): 628-633. Link to SFX for this item
16. Gerber, H. "Emerging immunotherapies targeting CD30 in Hodgkin's lymphoma." Biochemical Pharmacology 79.11 (2010): 1544-1552. Link to SFX for this item
17. Lee, Young-Jun J. "Therapeutic endovascular treatments for traumatic vertebral artery injuries." The Journal of trauma 62.4 (2007): 886-91. Link to SFX for this item
18. Schulz, H. "Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: A systematic review and meta-analysis." Journal of the National Cancer Institute 99.9 (2007): 706-714. Link to SFX for this item
19. Kyritsis, Chrissa P. "Central and peripheral nervous system toxicity of common chemotherapeutic agents." Cancer chemotherapy and pharmacology 63.5 (2008): 761-7. Link to Full Text for this item Link to SFX for this item
20. Kellie, C E E. "Vincristine revisited." Critical reviews in oncology/hematology 29.3 (1999): 267-87. Link to Full Text for this item Link to SFX for this item
View More...
View Less...
Select All Clear All

Expand list of advanced services Advanced
A service provided by the Library of the Wissenschaftspark Albert Einstein, Potsdam, Germany.
© 2005 SFX by Ex Libris Inc.